Skip to main content
Premium Trial:

Request an Annual Quote

Sema4, AdventHealth Collaborate on Analysis-Driven Personalized Health Program

NEW YORK – Sema4 said Tuesday that it has entered into a partnership with AdventHealth to expand the Orlando, Florida-based health system's existing personalized health program with Sema4's artificial intelligence and machine learning capabilities.

A Sema4 spokesperson said that this partnership is similar to one the company announced last month with NorthShore University HealthSystem in the Chicago area.

Under the new partnership, AdventHealth and Sema4 will structure and curate genomic and longitudinal clinical data for AI-based analysis using Sema4's Centrellis cloud-based health intelligence platform. Sema4, based in Stamford, Connecticut, will integrate the clinical and molecular data to build a dataset and analytical models to help predict the development of disease as well as patient response to potential treatments.

"This technology and collaboration will allow us to interpret vast amounts of clinical, genomic, and other patient data to discover and provide lifesaving treatments to patients who previously would not have had those options," AdventHealth CSO Steven Smith said in a statement.

"We are excited to use our sophisticated artificial intelligence tools to collaborate with AdventHealth scientists and clinicians to deliver improved health outcomes through data-driven insights," added Eric Schadt, founder and CEO of Sema4.

The collaboration will start with AdventHealth facilities in Central Florida, covering more than 20 hospitals and upwards of 2 million annual patient visits.

The AdventHealth Genomics and Personalized Health Program includes genome sequencing, genetic testing, genetic counseling, and precision medicine research. A centerpiece is WholeMe, a collaboration between the health system and Helix to offer free DNA testing to patients who might be at high risk of developing cardiovascular ailments.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.